162 related articles for article (PubMed ID: 32670868)
1. Translating the Immunobiology of SBRT to Novel Therapeutic Combinations for Advanced Prostate Cancer.
Adorno Febles VR; Blacksburg S; Haas JA; Wise DR
Front Oncol; 2020; 10():830. PubMed ID: 32670868
[TBL] [Abstract][Full Text] [Related]
2. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
[TBL] [Abstract][Full Text] [Related]
3. A Review of Stereotactic Body Radiation Therapy in the Management of Oligometastatic Prostate Cancer.
Zhang B; Leech M
Anticancer Res; 2020 May; 40(5):2419-2428. PubMed ID: 32366385
[TBL] [Abstract][Full Text] [Related]
4. Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.
Bouman-Wammes EW; van Dodewaard-De Jong JM; Dahele M; Cysouw MCF; Hoekstra OS; van Moorselaar RJA; Piet MAH; Verberne HJ; Bins AD; Verheul HMW; Slotman BJ; Oprea-Lager DE; Van den Eertwegh AJM
Clin Genitourin Cancer; 2017 Oct; 15(5):e773-e782. PubMed ID: 28462855
[TBL] [Abstract][Full Text] [Related]
5. Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy.
Carrasquilla M; Creswell ML; Pepin AN; Wang E; Forsthoefel M; McGunigal M; Bullock E; Lei S; Collins BT; Lischalk JW; Esposito G; Aghdam N; Kumar D; Suy S; Leger P; Hankins RA; Dawson NA; Collins SP
Front Oncol; 2020; 10():606260. PubMed ID: 33537236
[TBL] [Abstract][Full Text] [Related]
6. Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities.
Gomez-Iturriaga A; Büchser D; Lopez-Campos F; Maldonado X
Clin Transl Radiat Oncol; 2024 Mar; 45():100733. PubMed ID: 38322544
[TBL] [Abstract][Full Text] [Related]
7. Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).
Habl G; Straube C; Schiller K; Duma MN; Oechsner M; Kessel KA; Eiber M; Schwaiger M; Kübler H; Gschwend JE; Combs SE
BMC Cancer; 2017 May; 17(1):361. PubMed ID: 28532400
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes.
Hwang ME; Mayeda M; Liz M; Goode-Marshall B; Gonzalez L; Elliston CD; Spina CS; Padilla OA; Wenske S; Deutsch I
Radiat Oncol; 2019 Aug; 14(1):136. PubMed ID: 31375119
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer.
Oermann EK; Slack RS; Hanscom HN; Lei S; Suy S; Park HU; Kim JS; Sherer BA; Collins BT; Satinsky AN; Harter KW; Batipps GP; Constantinople NL; Dejter SW; Maxted WC; Regan JB; Pahira JJ; McGeagh KG; Jha RC; Dawson NA; Dritschilo A; Lynch JH; Collins SP
Technol Cancer Res Treat; 2010 Oct; 9(5):453-62. PubMed ID: 20815416
[TBL] [Abstract][Full Text] [Related]
10. Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.
Dess RT; Jackson WC; Suy S; Soni PD; Lee JY; Abugharib AE; Zumsteg ZS; Feng FY; Hamstra DA; Collins SP; Spratt DE
Cancer; 2017 May; 123(9):1635-1642. PubMed ID: 28001303
[TBL] [Abstract][Full Text] [Related]
11. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
12. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy.
Berkovic P; De Meerleer G; Delrue L; Lambert B; Fonteyne V; Lumen N; Decaestecker K; Villeirs G; Vuye P; Ost P
Clin Genitourin Cancer; 2013 Mar; 11(1):27-32. PubMed ID: 23010414
[TBL] [Abstract][Full Text] [Related]
13. SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer.
Azzam G; Lanciano R; Arrigo S; Lamond J; Ding W; Yang J; Hanlon A; Good M; Brady L
Front Oncol; 2015; 5():101. PubMed ID: 26000249
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiation therapy (SBRT) delays the emergence of castration resistance in patients with oligometastatic prostate cancer.
Martínez-Fernández MI; Pérez Gracia JL; Gil-Bazo I; Martínez-Monge R
Clin Transl Oncol; 2016 Jul; 18(7):743-7. PubMed ID: 26482722
[TBL] [Abstract][Full Text] [Related]
15. Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer.
Bhattasali O; Chen LN; Tong M; Lei S; Collins BT; Krishnan P; Kalhorn C; Lynch JH; Suy S; Dritschilo A; Dawson NA; Collins SP
Front Oncol; 2013 Dec; 3():293. PubMed ID: 24350058
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic Body Radiotherapy - Current Indications.
Burkoň P; Slavik M; Kazda T; Pospíšil P; Prochazka T; Vrzal M; Šlampa P
Klin Onkol; 2019; 32(1):10-24. PubMed ID: 30894002
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer.
Kim HJ; Phak JH; Kim WC
Prostate Int; 2015 Dec; 3(4):118-22. PubMed ID: 26779457
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15).
Aghdam N; Pepin A; Buchberger D; Hirshberg J; Lei S; Ayoob M; Danner M; Yung T; Kumar D; Collins BT; Lynch J; Kataria S; Suy S; Collins SP
Front Oncol; 2020; 10():1060. PubMed ID: 32719744
[No Abstract] [Full Text] [Related]
20. Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer.
Lischalk JW; Burke A; Chew J; Elledge C; Gurka M; Marshall J; Pishvaian M; Collins S; Unger K
J Gastrointest Cancer; 2018 Jun; 49(2):116-123. PubMed ID: 28044263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
